WO2021153771A1 - ヒアルロン酸産生促進剤 - Google Patents

ヒアルロン酸産生促進剤 Download PDF

Info

Publication number
WO2021153771A1
WO2021153771A1 PCT/JP2021/003360 JP2021003360W WO2021153771A1 WO 2021153771 A1 WO2021153771 A1 WO 2021153771A1 JP 2021003360 W JP2021003360 W JP 2021003360W WO 2021153771 A1 WO2021153771 A1 WO 2021153771A1
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
skin
vitamin
wavelength
ultraviolet rays
Prior art date
Application number
PCT/JP2021/003360
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
宮沢　和之
レノ ジレ
ビアンカ マッカーシー
哲也 金丸
Original Assignee
株式会社 資生堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 資生堂 filed Critical 株式会社 資生堂
Priority to JP2021574715A priority Critical patent/JPWO2021153771A1/ja
Priority to CN202180011837.4A priority patent/CN115052579A/zh
Publication of WO2021153771A1 publication Critical patent/WO2021153771A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a hyaluronic acid production promoter containing a wavelength converting substance, a composition and a product containing such a hyaluronic acid production promoter, and a method for promoting the production of hyaluronic acid in the skin using them.
  • the harmful effects of ultraviolet rays on the skin include, for example, skin cancer, photoaging, age spots, wrinkles, and inflammation, which are not preferable from the viewpoint of health and beauty.
  • ultraviolet rays for the purpose of bactericidal effect, considering the balance with the harmful effects of ultraviolet rays, the focus is on protecting them rather than actively using them. The current situation.
  • UV-cut film Therefore, many measures have been taken to protect the skin from UV rays. For example, the use of sunscreen, indoor activities that are not exposed to sunlight, UV-cut hats and clothing, and the use of UV-cut film.
  • An object of the present invention is to provide a novel hyaluronic acid production promoter using ultraviolet rays.
  • the present inventors have conducted diligent research so that ultraviolet rays can be effectively used for the skin.
  • a hyaluronic acid production promoter that converts the wavelength of ultraviolet rays and promotes the production of hyaluronic acid in skin cells.
  • the wavelength conversion substance is a hyaluronic acid production promoter that converts the wavelength of ultraviolet rays contained in incident light and emits emitted light having a wavelength longer than the wavelength of the ultraviolet rays.
  • the wavelength converting substance is selected from allophycocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin.
  • One or more phycocyanin proteins selected from zinc oxide phosphors, magnesium titanate phosphors, and calcium phosphate phosphors; vitamin A, ⁇ -carotenoids, vitamin K, vitamins Selected from B1, Vitamin B2, Vitamin B6, Vitamin B12, Folic Acid, Niacin, Lycopine, Cutinashi, Benibana, Ukon, Cochinil, Perilla, Red Cabbage, Flavonoids, Carotenoids, Kinoids, Porphyrins, Anthocyanins, and Polyphenols 1 Species or multiple components; and / or Red 401, Red 227, Red 504, Red 218, Orange 205 P, Yellow 4, Yellow 5, Green 201, Phycocyanin Conch, Blue 1, Selected from 2,4-diaminophenoxyethanol hydrochloride, Arizulin purple SS, purple 401, black 401, herringdon pink, yellow 401, phycocyanin yellow G, blue 404, red 104, and metaamin
  • the hyaluronic acid production promoter according to any one of (1) to (3), which comprises one or more kinds of pigments.
  • the wavelength converting substance is selected from allophycocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin.
  • One or more phycoerythrinth proteins one or more inorganic phosphors selected from zinc oxide phosphors, magnesium titanate phosphors, and calcium phosphate phosphors; and / or vitamin B1, vitamin B2,
  • the hyaluronic acid production promoter according to (4) which comprises one or more kinds of vitamin B selected from vitamin B6 and vitamin B12.
  • (6) A composition containing the hyaluronic acid production promoter according to any one of (1) to (5).
  • the composition according to (6), wherein the composition is a composition for external use on the skin, and is for promoting the production of hyaluronic acid in the skin by exposing the skin to light containing ultraviolet rays.
  • the present invention can exert a favorable effect on the skin by effectively utilizing ultraviolet rays to promote the production of hyaluronic acid in the skin.
  • ultraviolet rays are not preferable to the skin, so it is common general technical knowledge in this field to take measures to prevent the skin from being exposed to ultraviolet rays as much as possible.
  • the present invention is very surprising because it is based on the finding that ultraviolet rays are used in reverse to give a favorable effect to the skin.
  • the present invention also provides new uses for the above-mentioned compounds that have been conventionally mainly used as pigments, pigments, ultraviolet scattering agents, ultraviolet absorbers, nutritional components, antioxidants, and the like. Further, the present invention may lead to improvement of quality of life such that even a person who has avoided ultraviolet rays as much as possible for beauty and health reasons can feel like going out positively.
  • FIG. 1 shows the production of hyaluronic acid by fibroblasts (in the figure, P ⁇ 0.01 and P ⁇ 0.05 indicate the results of t-test for UV irradiation).
  • the hyaluronic acid production promoter of the present invention contains a wavelength converting substance as an active ingredient.
  • the wavelength conversion substance refers to a substance that converts the wavelength of ultraviolet rays contained in incident light and emits emitted light having a wavelength longer than the wavelength of the ultraviolet rays.
  • Ultraviolet rays may include UVA, UVB, UVC and the like.
  • ultraviolet light is light having a peak wavelength between 200 nm and 400 nm.
  • the incident light such as sunlight may contain ultraviolet rays.
  • the incident light may be ultraviolet rays, or artificially generated ultraviolet rays may be used.
  • the emitted light emitted by the wavelength converting substance has a longer wavelength than ultraviolet rays, and has a peak wavelength of preferably 450 nm to 700 nm, more preferably 500 nm to 700 nm.
  • the emitted light is, for example, but not limited to, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, It may have one or more peaks in 650nm, 660nm, 670nm, 680nm, 690nm, 700nm, or any range of these values, or in red light, orange light, green light, blue light, etc.
  • the wavelength-converting material exhibits a main wavelength of 450 nm to 700 nm, more preferably 500 nm to 700 nm, of light emitted when excited by excitation light of 200 nm to 400 nm.
  • wavelength converters include: allophicocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, R-phy Phycoerythrin and other phycocyanins; vitamin A, ⁇ -carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, lycopene, cutinashi, benibana, turmeric, cochineal, perilla, red cabbage, flavonoids, carotenoids , Kinoids, porphyrins, anthocyanins, polyphenols, etc.
  • Red 401, Red 227, Red 504, Red 218, Orange 205 P Yellow 4, Yellow 5, Green 201 No., Pyranin Conc, Blue No. 1, Hydrochloride 2,4-diaminophenoxyethanol, Arizulin Purple SS, Purple No. 401, Black No. 401, Herringdon Pink, Yellow No. 401, Benchin Yellow G, Blue No. 404, Red No. 104, Dyes such as metaaminophenol; phosphors doped with inorganic compounds to have fluorescence, for example, blue phosphors containing the amorphous silica particles described in Patent No. 6424656, cerium, phosphorus and / or magnesium.
  • a red phosphor containing a compound in which europium is activated in a mixed crystal of alkaline earth metal sulfide and gallium compound described in Patent No. 6361416 zinc oxide phosphor described in International Publication No. 2018/004006, special feature.
  • Examples thereof include the zinc oxide phosphor described in Kai 2018-131422; the inorganic phosphor described in JP-A-5-117127; and the like.
  • the inorganic phosphor can represent zinc oxide as ZnO: Zn, Zn 1 + z , ZnO 1-x , as described in WO 2018/004006, eg, zinc sulfide, zinc sulfate.
  • the wavelength conversion substance may be obtained from natural products such as animals, plants, and algae by a method such as extraction, or may be obtained by an artificial method such as chemical synthesis.
  • the phycobiliprotein is algae such as blue-green algae such as Spirulina platensis and red algae such as Porphyridium purpureum. It may be prepared by extraction.
  • the zinc oxide phosphor may be produced, for example, by the methods described in International Publication No. 2018/004006, JP-A-2018-131422, and JP-A-5-117127.
  • the magnesium titanate phosphor may be produced by the method described in JP-A-2017-88719.
  • the calcium phosphate phosphor may be produced by the method described in WO 2018/117117.
  • wavelength conversion substances may be composed of the components exemplified above, may be contained, or may be used alone or in combination of a plurality of types, as long as the wavelength conversion effect of the present invention is not impaired. good.
  • other wavelength converting substances such as vitamin B (vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.) may be mixed with the phycobiliprotein or the inorganic phosphor to aim for a synergistic effect.
  • these components are examples, and any substance exhibiting the wavelength conversion effect of the present invention can be used.
  • the content of the wavelength conversion substance in the hyaluronic acid production promoter, composition or product of the present invention is not particularly limited as long as the wavelength conversion effect of the present invention is not impaired, and the type of the wavelength conversion substance or the hyaluronic acid production promoter or It can be appropriately determined depending on the use of the composition. For example, it is arbitrary within the range of 0.01 to 99.99% by weight, 0.1% to 999% by weight, and the like.
  • Promotion of hyaluronic acid production refers to promotion of hyaluronic acid production in animal cells including humans, for example, skin fibroblasts and / or keratinized cells, though not limited to. It is known that the amount of hyaluronic acid in skin cells decreases due to ultraviolet rays, aging, and the like. When the production of hyaluronic acid in the skin is promoted, it is expected to have effects such as prevention / improvement of wrinkles, moisturization, improvement of skin firmness, and suppression of inflammation caused by ultraviolet rays.
  • the hyaluronic acid production promoting effect may be measured by measuring the viability and proliferation of cells using Alamar Blue, for example, as in Examples, other dye assays, and mitochondrial membrane potential-dissimilar dye assays. , Elastase cleavage dye assay, ATP, ADE assay, glycolytic flux and oxygen consumption assay, etc. can be used.
  • the administration form of the hyaluronic acid production promoter and the composition of the present invention is arbitrary, but in order to promote the production of hyaluronic acid in the skin by exposing the skin to light containing ultraviolet rays, pharmaceuticals, quasi-drugs, cosmetics, etc. Skin external preparations may be preferred.
  • the dosage form, application method, number of administrations and the like can be arbitrarily determined.
  • the dosage form, application method, number of administrations and the like can be arbitrarily determined.
  • lotion, spray, oil, cream, milky lotion, gel, sunscreen, suntan, etc. regularly or irregularly, for example, once to several times a day, such as in the morning, noon, and evening. It may be applied to the skin each time before going out, outdoor activities, marine sports, skiing, etc. before being expected to be exposed to the sun.
  • the hyaluronic acid production promoter and composition of the present invention may be used, for example, as an excipient, a preservative, a thickener, a binder, a disintegrant, a dispersant, a stabilizer, a gelling agent, as required.
  • the present invention contains the hyaluronic acid production promoter of the present invention, and for promoting the production of hyaluronic acid in the skin by exposing the skin to light including ultraviolet rays, for example, a sun visor, a hat, clothing, gloves, and the like.
  • light including ultraviolet rays, for example, a sun visor, a hat, clothing, gloves, and the like.
  • products such as screen films, window sprays and creams, window materials and wall materials. Similar to the above, the use of additives and the like in the product of the present invention and the form of the product are also arbitrary.
  • the present invention also provides a method for producing the hyaluronic acid production promoter, composition or product of the present invention. It also provides a method for promoting the production of hyaluronic acid in the target skin, wherein the method applies the hyaluronic acid production promoter or composition of the present invention to the target skin, and the hyaluron.
  • the hyaluronic acid production promoter, composition and product convert the wavelength of ultraviolet rays contained in the incident light to emit emitted light having a wavelength longer than the wavelength of the ultraviolet rays, preferably peaking at 200 nm to 400 nm.
  • Ultraviolet rays having a wavelength are passed through as light having a peak wavelength of preferably 450 nm to 700 nm, more preferably 500 nm to 700 nm.
  • the methods for promoting the production of hyaluronic acid in the subject's skin are for cosmetic purposes and may not be the therapeutic methods used by doctors and healthcare professionals.
  • the present invention also provides a cosmetological counseling method that supports a cosmetological act of the subject, including presenting the cosmetological method, the hyaluronic acid production promoter, the composition or the product of the present invention to the subject.
  • Wavelength conversion substances were prepared as follows. (1) B-phycoerythrin B-phycoerythrin is obtained from Porphyridium Cruentum extract, and its absorption spectrum has a peak wavelength at 305 nm, and its emission spectrum peaks at 570 nm and 610 nm. Had a wavelength. (2) C-phycocyanin C-phycocyanin is obtained from a Spirulina platensis extract, and its absorption spectrum has a peak wavelength at 350 nm, and its emission spectrum has a peak wavelength at 640 nm and 700 nm. Was there.
  • Lumate G is a zinc oxide phosphor obtained by doping ZnO with a sulfur-containing compound and then firing it as described in International Publication No. 2018/004006.
  • the absorption spectrum has a peak wavelength at 365 nm, and the emission spectrum peaks at 510 nm. Had a wavelength.
  • Magnesium titanate phosphor Lumate R manufactured by Sakai Chemical Industry Co., Ltd. was used.
  • Lumate R is a magnesium titanate phosphor doped with MgTiO 3 with manganese.
  • the absorption spectrum has a peak wavelength at 365 nm, and the emission spectrum has a peak wavelength in the band of 660 to 680 nm.
  • Calcium phosphate phosphor Lumate B manufactured by Sakai Chemical Industry Co., Ltd. was used. Lumate B is a phosphor doped with calcium phosphate with cerium, and its emission spectrum has a peak wavelength in the band of 350 to 700 nm.
  • the wavelength conversion substances (1) to (2) were dissolved in water to prepare a solution having a concentration of 1%.
  • the wavelength conversion substances (3) to (5) were dispersed in the acrylic polymer to prepare a 10% film.
  • Experiment 1-2 Preparation of cell sample A cell sample was prepared as follows. 1. Human skin fibroblasts purchased from Kurabo were used. The cell suspension (1 mL) stored in liquid nitrogen was thawed in a hot water bath (37 ° C.) to the extent that small ice pellets remained, and then diluted with 9 mL of warm medium. 2. The dilutions were gently mixed, then transferred to a T75 flask and incubated overnight at 37 ° C. 3. The next day, the medium was replaced with 10 mL of fresh medium. 4. The medium was changed regularly (once every two days) to continue cell growth. During that time, the cells were observed using a microscope to confirm that the cells were growing in the correct morphology. 5.
  • Cells were passaged after reaching approximately 80% confluence. Cell passage was performed by washing the cells once with 10 mL of warm PBS, adding 5 mL of warm trypsin to the T75 flask, covering the bottom of the flask with trypsin solution, and aspirating at room temperature for 1 minute. .. 6. The flask was allowed to stand in an oven at 37 ° C for (maximum) 2 minutes. The cells were observed using a microscope, and it was confirmed that the cells were small and oval. 7. After that, the side of the T75 flask was tapped to release the cells. The cells were observed using a microscope, and it was confirmed that the cells were moving freely. 8.
  • Fibroblasts should reach the desired confluency in 24 hours at a cell density of 2 ⁇ 10 4 cells / well. If the cell density is as low as 1 ⁇ 10 4 cells / well, for example. It takes 48 hours for fibroblasts to reach the desired confluency.) 12. Twenty-four hours before irradiation, the medium was changed to a medium containing a low concentration of serum (0.5% FCS).
  • Experiment 1-3 UV irradiation 1. At least 30 minutes before irradiation, the solar simulator was turned on to warm up the lamp. The solar simulator was set to use the UG11 filter. The UG11 filter is a filter that allows only UVB to pass and cuts light of other wavelengths. The UV light that passed through the UG11 filter had a peak wavelength between 300 nm and 385 nm. 2. The temperature control plate was turned on and set to 33 ° C. 3. The cells prepared in Experiment 1-2 were washed once with warm PBS. 4. 0.5 mL of warm PBS was added to each well. 5. The cell wells were placed on a plate and irradiated at a dose of 100 mJ / cm 2 without using a wavelength converter.
  • a sample in which the cells were directly irradiated with UV light without placing a plate or film of a wavelength converting substance on the cell wells and a sample in which the cells were cultured in a dark place without irradiating UV light were prepared. 8. After irradiation, the solution was replaced with 0.5% DMEM and the plate was returned to the incubator at 37 ° C.
  • Experiment 1-4 Measurement of hyaluronic acid production promoting effect QnE Hyaluronic Acid (HA) ELISA Assay Kit (Funakoshi, Cat. # BTP-) using cells held in an incubator for 48 hours after Experiment 1-3. 96200) was used according to the product description to measure the concentration of hyaluronic acid produced by fibroblasts in the culture medium.
  • HA Hyaluronic Acid
  • Fig. 1 The results are shown in Fig. 1.
  • the hyaluronic acid concentration was lower than that of the control (Sham) with and without UV irradiation (UV).
  • UV UV was irradiated through the wavelength conversion substance
  • the amount of hyaluronic acid increased as compared with the UV irradiation group (UV).
  • B-phycoerythrin, C-phycocyanin, and magnesium titanate phosphors were used, the amount of hyaluronic acid was increased rather than in the group without UV irradiation (Sham).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2021/003360 2020-01-31 2021-01-29 ヒアルロン酸産生促進剤 WO2021153771A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021574715A JPWO2021153771A1 (zh) 2020-01-31 2021-01-29
CN202180011837.4A CN115052579A (zh) 2020-01-31 2021-01-29 透明质酸产生促进剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020015703 2020-01-31
JP2020-015703 2020-01-31

Publications (1)

Publication Number Publication Date
WO2021153771A1 true WO2021153771A1 (ja) 2021-08-05

Family

ID=77078959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/003360 WO2021153771A1 (ja) 2020-01-31 2021-01-29 ヒアルロン酸産生促進剤

Country Status (3)

Country Link
JP (1) JPWO2021153771A1 (zh)
CN (1) CN115052579A (zh)
WO (1) WO2021153771A1 (zh)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117127A (ja) * 1991-10-02 1993-05-14 Shiseido Co Ltd 蛍光化粧料
JP2009209093A (ja) * 2008-03-04 2009-09-17 Shiseido Co Ltd 皮膚バリアー機能回復促進剤及び皮膚外用剤
JP2015074623A (ja) * 2013-10-08 2015-04-20 二村　芳弘 コラーゲン産生作用を有する新規な誘導体及びその製造方法
CN105055251A (zh) * 2015-08-29 2015-11-18 云南蓝钻生物科技股份有限公司 一种抗衰老化妆品及其制备方法
JP2016500052A (ja) * 2012-09-20 2016-01-07 エコシステム フィコシアニンを抽出および安定化する方法とその利用
JP2017122075A (ja) * 2016-01-08 2017-07-13 花王株式会社 水中油型皮膚化粧料
WO2017142057A1 (ja) * 2016-02-18 2017-08-24 ロート製薬株式会社 皮膚外用組成物
KR20190005369A (ko) * 2017-07-06 2019-01-16 한국 한의학 연구원 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물
JP2020183356A (ja) * 2019-05-08 2020-11-12 Dic株式会社 フィコシアニンを有効成分として含有することを特徴とする化粧料

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB639086A (en) * 1947-01-17 1950-06-21 British Thomson Houston Co Ltd Improvements in and relating to magnesium titanate phosphors
AU2003230031A1 (en) * 2002-05-23 2003-12-12 Anglia Polytechnic University Drink containing fluorescent agent
TW201216997A (en) * 2010-10-26 2012-05-01 Yen-Horng Tsou for preventing skin tissue damage due to short wavelength light irradiation and reflecting fluorescent colors to achieve the effect of make-up
TW201613750A (en) * 2015-08-13 2016-04-16 Zheng-Hong Shi Pulsed color light dressing film product
EP3480279A4 (en) * 2016-06-30 2020-01-01 Sakai Chemical Industry Co., Ltd. ZINC OXIDE PHOSPHORUS AND METHOD FOR PRODUCING THE SAME
WO2020202764A1 (ja) * 2019-04-05 2020-10-08 株式会社 資生堂 細胞賦活剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117127A (ja) * 1991-10-02 1993-05-14 Shiseido Co Ltd 蛍光化粧料
JP2009209093A (ja) * 2008-03-04 2009-09-17 Shiseido Co Ltd 皮膚バリアー機能回復促進剤及び皮膚外用剤
JP2016500052A (ja) * 2012-09-20 2016-01-07 エコシステム フィコシアニンを抽出および安定化する方法とその利用
JP2015074623A (ja) * 2013-10-08 2015-04-20 二村　芳弘 コラーゲン産生作用を有する新規な誘導体及びその製造方法
CN105055251A (zh) * 2015-08-29 2015-11-18 云南蓝钻生物科技股份有限公司 一种抗衰老化妆品及其制备方法
JP2017122075A (ja) * 2016-01-08 2017-07-13 花王株式会社 水中油型皮膚化粧料
WO2017142057A1 (ja) * 2016-02-18 2017-08-24 ロート製薬株式会社 皮膚外用組成物
KR20190005369A (ko) * 2017-07-06 2019-01-16 한국 한의학 연구원 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물
JP2020183356A (ja) * 2019-05-08 2020-11-12 Dic株式会社 フィコシアニンを有効成分として含有することを特徴とする化粧料

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATO, TOSHIMITSU: "Utilization of Spirulina blue colorant: Especially for frozen desserts and drinks", NEW FOOD INDUSTRY, vol. 29, no. 3, 30 November 1986 (1986-11-30), pages 17 - 21, XP009530217, ISSN: 0547-0277 *
SAKAI CHEMICAL INDUSTRY CO., LTD.: "Shining new cosmetic raw material, Inorganic fluorescent powder Lumate@ series", FUREGURANSU JANARU - FRAGRANCE JOURNAL., vol. 43, no. 7, 30 June 2015 (2015-06-30), JP, pages 62 - 63, XP009530263, ISSN: 0288-9803 *

Also Published As

Publication number Publication date
CN115052579A (zh) 2022-09-13
JPWO2021153771A1 (zh) 2021-08-05

Similar Documents

Publication Publication Date Title
WO2020202764A1 (ja) 細胞賦活剤
WO2021153773A1 (ja) 光老化抑制剤
WO2021153771A1 (ja) ヒアルロン酸産生促進剤
WO2021153781A1 (ja) コラーゲン糖化抑制剤
WO2021153776A1 (ja) 血管新生抑制剤
WO2021153785A1 (ja) コラーゲン産生能の維持または促進剤
WO2020204193A9 (ja) 紫外線波長変換物質を含有する組成物
WO2021153780A1 (ja) 抗酸化剤又は皮膚ストレス抑制剤
WO2021153783A1 (ja) 炎症抑制剤
WO2021153788A1 (ja) 皮膚バリア機能亢進剤
JP7509541B2 (ja) 紫外線波長変換物質及び有機系油相増粘剤を含有する乳化組成物
JP7509542B2 (ja) 紫外線波長変換物質を含有する組成物
JP7509540B2 (ja) 紫外線波長変換物質を含有する水中油型乳化組成物
US20220160604A1 (en) Emulsion composition comprising ultraviolet wavelength conversion substance and organic oily phase thickener
JP2024031642A (ja) 可視光によりリボフラビンの生理作用を増強するための美容方法
JP2024031635A (ja) 可視光によりフラボノイドの生理作用を増強するための美容方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21747848

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021574715

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21747848

Country of ref document: EP

Kind code of ref document: A1